×
Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Xenetic Biosciences EBITDA 2013-2024 | XBIO

Xenetic Biosciences ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
  
Xenetic Biosciences Annual EBITDA
(Millions of US $)
2024 $-4
2023 $-5
2022 $-7
2021 $-6
2020 $-14
2019 $-10
2018 $-7
2017 $-4
2016 $-47
2015 $-10
2014 $-13
2013 $-8
2012 $-6
2011 $-6
Xenetic Biosciences Quarterly EBITDA
(Millions of US $)
2024-12-31 $-1
2024-09-30 $-1
2024-06-30 $-1
2024-03-31 $-1
2023-12-31 $-1
2023-09-30 $-1
2023-06-30 $-1
2023-03-31 $-1
2022-12-31 $-2
2022-09-30 $-1
2022-06-30 $-3
2022-03-31 $-2
2021-12-31 $-2
2021-09-30 $-1
2021-06-30 $-1
2021-03-31 $-1
2020-12-31 $-10
2020-09-30 $-1
2020-06-30 $-1
2020-03-31 $-1
2019-12-31 $-1
2019-09-30 $-6
2019-06-30 $-1
2019-03-31 $-1
2018-12-31 $-2
2018-09-30 $-2
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $4
2017-09-30 $-2
2017-06-30 $-3
2017-03-31 $-3
2016-12-31 $-3
2016-09-30 $-2
2016-06-30 $-43
2016-03-31 $-2
2015-12-31 $-3
2015-09-30 $-4
2015-06-30 $-1
2015-03-31 $-2
2014-12-31 $-4
2014-09-30 $-3
2014-06-30 $-3
2014-03-31 $-3
2013-12-31 $-4
2013-09-30 $-3
2013-06-30 $-1
2013-03-31 $-1
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.004B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $74.838B 29.53
Zoetis (ZTS) United States $73.729B 27.81
Takeda Pharmaceutical (TAK) Japan $47.315B 10.47
Daiichi Sankyo, - (DSNKY) Japan $45.571B 27.77
Sandoz Group AG (SDZNY) Switzerland $18.445B 0.00
Merck (MKKGY) Germany $17.719B 14.66
Astellas Pharma (ALPMY) Japan $17.481B 12.39
Summit Therapeutics (SMMT) United States $14.230B 0.00
United Therapeutics (UTHR) United States $13.845B 12.53
Shionogi (SGIOY) Japan $12.760B 12.78
Corcept Therapeutics (CORT) United States $12.051B 92.11
Neurocrine Biosciences (NBIX) United States $11.027B 33.62
IPSEN (IPSEY) France $9.797B 0.00
Orion OYJ (ORINY) Finland $8.460B 23.98
Madrigal Pharmaceuticals (MDGL) United States $7.314B 0.00
Stevanato Group S.p.A (STVN) Italy $6.184B 39.27
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.813B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.254B 10.76
Grifols, S.A (GRFS) Spain $4.889B 0.00
Ionis Pharmaceuticals (IONS) United States $4.796B 0.00
Soleno Therapeutics (SLNO) United States $3.277B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.121B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.945B 12.01
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.598B 16.11
NewAmsterdam Pharma (NAMS) Netherlands $2.248B 0.00
Hypermarcas (HYPMY) Brazil $2.131B 8.41
Recursion Pharmaceuticals (RXRX) United States $2.127B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.915B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.567B 0.00
Guardian Pharmacy Services (GRDN) United States $1.346B 0.00
Indivior (INDV) United States $1.314B 5.71
ARS Pharmaceuticals (SPRY) United States $1.234B 157.25
Evotec AG (EVO) Germany $1.184B 0.00
Dyne Therapeutics (DYN) United States $1.183B 0.00
Ardelyx (ARDX) United States $1.170B 0.00
Ocular Therapeutix (OCUL) United States $1.166B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.104B 44.67
Enliven Therapeutics (ELVN) United States $0.964B 0.00
Collegium Pharmaceutical (COLL) United States $0.959B 5.09
Harrow (HROW) United States $0.948B 0.00
Xeris Biopharma Holdings (XERS) United States $0.845B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.757B 0.00
Bioventus (BVS) United States $0.750B 19.47
Xencor (XNCR) United States $0.750B 0.00
Cronos Group (CRON) Canada $0.692B 0.00
KalVista Pharmaceuticals (KALV) United States $0.574B 0.00
Organogenesis (ORGO) United States $0.548B 0.00
USANA Health Sciences (USNA) United States $0.510B 10.37
Savara (SVRA) United States $0.478B 0.00
Elite Pharmaceuticals (ELTP) United States $0.465B 0.00
Akebia Therapeutics (AKBA) United States $0.454B 0.00
Relay Therapeutics (RLAY) United States $0.444B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.442B 0.00
Verve Therapeutics (VERV) United States $0.406B 0.00
Zevra Therapeutics (ZVRA) United States $0.405B 0.00
Siga Technologies (SIGA) United States $0.391B 6.68
Tourmaline Bio (TRML) United States $0.391B 0.00
Altimmune (ALT) United States $0.385B 0.00
Oruka Therapeutics (ORKA) United States $0.384B 0.00
Aldeyra Therapeutics (ALDX) United States $0.343B 0.00
Heron Therapeutics (HRTX) United States $0.335B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.321B 19.14
Amylyx Pharmaceuticals (AMLX) United States $0.314B 0.00
OmniAb (OABI) United States $0.293B 0.00
Aquestive Therapeutics (AQST) United States $0.287B 0.00
Esperion Therapeutics (ESPR) United States $0.285B 36.00
CytoDyn (CYDY) United States $0.283B 0.00
ProKidney (PROK) United States $0.256B 0.00
Innate Pharma SA (IPHYF) France $0.243B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.235B 73.50
Nature's Sunshine Products (NATR) United States $0.232B 27.28
Wellgistics Health (WGRX) United States $0.224B 0.00
Avita Medical (RCEL) United States $0.213B 0.00
Profound Medical (PROF) Canada $0.175B 0.00
Nanobiotix S.A (NBTX) France $0.169B 0.00
MediWound (MDWD) Israel $0.168B 0.00
Aclaris Therapeutics (ACRS) United States $0.165B 0.00
Korro Bio (KRRO) United States $0.163B 0.00
Inhibikase Therapeutics (IKT) United States $0.163B 0.00
Lyell Immunopharma (LYEL) United States $0.159B 0.00
Protara Therapeutics (TARA) United States $0.157B 0.00
4D Molecular Therapeutics (FDMT) United States $0.150B 0.00
Larimar Therapeutics (LRMR) United States $0.138B 0.00
Nektar Therapeutics (NKTR) United States $0.127B 0.00
Journey Medical (DERM) United States $0.123B 0.00
Champions Oncology (CSBR) United States $0.120B 19.73
Enanta Pharmaceuticals (ENTA) United States $0.118B 0.00
Regulus Therapeutics (RGLS) United States $0.116B 0.00
Lexeo Therapeutics (LXEO) United States $0.115B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.115B 0.00
Telomir Pharmaceuticals (TELO) United States $0.096B 0.00
VAXART, INC (VXRT) United States $0.093B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
OptiNose (OPTN) United States $0.092B 0.00
Avalo Therapeutics (AVTX) United States $0.085B 0.00
Arch Biopartners (ACHFF) Canada $0.082B 0.00
Cardiol Therapeutics (CRDL) Canada $0.080B 0.00
Galectin Therapeutics (GALT) United States $0.077B 0.00
Inotiv (NOTV) United States $0.075B 0.00
Cassava Sciences (SAVA) United States $0.072B 0.00
ESSA Pharma (EPIX) Canada $0.070B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.069B 0.00
Nutriband (NTRB) United States $0.068B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.065B 0.00
Assertio Holdings (ASRT) United States $0.065B 0.00
Acrivon Therapeutics (ACRV) United States $0.064B 0.00
Vivani Medical (VANI) United States $0.062B 0.00
Pyxis Oncology (PYXS) United States $0.060B 0.00
Unicycive Therapeutics (UNCY) United States $0.060B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.059B 0.00
Fractyl Health (GUTS) United States $0.058B 0.00
PMV Pharmaceuticals (PMVP) United States $0.057B 0.00
Context Therapeutics (CNTX) United States $0.055B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
AleAnna (ANNA) United States $0.052B 0.00
Metagenomi (MGX) United States $0.051B 0.00
ElectroCore (ECOR) United States $0.048B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
Dominari Holdings (DOMH) United States $0.044B 0.00
Iterum Therapeutics (ITRM) Ireland $0.043B 0.00
Prelude Therapeutics (PRLD) United States $0.042B 0.00
Century Therapeutics (IPSC) United States $0.041B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.041B 0.00
Surrozen (SRZN) United States $0.038B 0.00
SCYNEXIS (SCYX) United States $0.037B 0.00
NRx Pharmaceuticals (NRXP) United States $0.035B 0.00
Tempest Therapeutics (TPST) United States $0.034B 0.00
CASI Pharmaceuticals (CASI) China $0.033B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.032B 0.00
Karyopharm Therapeutics (KPTI) United States $0.031B 0.00
FibroGen (FGEN) United States $0.031B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
DURECT (DRRX) United States $0.025B 0.00
VYNE Therapeutics (VYNE) United States $0.024B 0.00
Mural Oncology (MURA) Ireland $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Enlivex Therapeutics (ENLV) Israel $0.021B 0.00
Jupiter Neurosciences (JUNS) United States $0.020B 0.00
BioVie (BIVI) United States $0.018B 0.00
Mannatech (MTEX) United States $0.017B 6.90
Lipocine (LPCN) United States $0.017B 0.00
Vivos Therapeutics (VVOS) United States $0.017B 0.00
MEI Pharma (MEIP) United States $0.015B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Scienture Holdings (SCNX) United States $0.013B 0.00
Carisma Therapeutics (CARM) United States $0.013B 0.00
Citius Pharmaceuticals (CTXR) United States $0.013B 0.00
Incannex Healthcare (IXHL) Australia $0.012B 0.00
Minerva Neurosciences (NERV) United States $0.012B 8.95
TherapeuticsMD (TXMD) United States $0.011B 0.00
Biomerica (BMRA) United States $0.010B 0.00
Cosmos Health (COSM) United States $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
BioLineRx (BLRX) Israel $0.010B 0.00
ProPhase Labs (PRPH) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 2.89
Relmada Therapeutics (RLMD) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
Nuvilex (PMCB) United States $0.009B 0.00
Talphera (TLPH) United States $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Lyra Therapeutics (LYRA) United States $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Ainos (AIMD) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Alaunos Therapeutics (TCRT) United States $0.002B 0.00
CERo Therapeutics Holdings (CERO) United States $0.002B 0.00
Heatwurx (PCSA) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
SHINECO (SISI) China $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Petros Pharmaceuticals (PTPI) United States $0.001B 0.00
TransCode Therapeutics (RNAZ) United States $0.000B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00